« Back to Record
Citation APA

Tagliamento, M., Delucchi, V., Rossi, G., Cella, E., Barcellini, L., Bragoni, A., Chiappe, E., Lambertini, M., Boni, L., Ferrara, R., Brandão, M., Schmitt-Opitz, I., Dingemans, A.-M. C., Besse, B., Michiels, S., & Blondeaux, E. (2025). 150P: Pathologic complete response (pCR) and major pathologic response (MPR) as surrogate endpoints of survival in immunotherapy trials for early-stage NSCLC. Journal of Thoracic Oncology,(20(3):S106–7).


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/401659

Tagliamento, M., Delucchi, V., Rossi, G., Cella, E., Barcellini, L., Bragoni, A., Chiappe, E., Lambertini, M., Boni, L., Ferrara, R., Brandão, M., Schmitt-Opitz, I., Dingemans, A.-M. C., Besse, B., Michiels, S., & Blondeaux, E. (2025). 150P: Pathologic complete response (pCR) and major pathologic response (MPR) as surrogate endpoints of survival in immunotherapy trials for early-stage NSCLC. Journal of Thoracic Oncology,(20(3):S106–7).